Translating the receptor operational model to bedside opioid reasoning in perioperative care

1 Introduction

Perioperative opioid practice can appear paradoxical if we assume that a high-affinity partial agonist simply “blocks” a full agonist at μ-opioid receptors (MOR). Yet clinical data point to an endpoint asymmetry: buprenorphine shows a ceiling in respiratory depression without a clear analgesic ceiling, whereas fentanyl can provide potent intraoperative analgesia while driving steep respiratory depression (1). Herein, we use the receptor operational model (2) to treat receptor engagement as an upstream input and perioperative endpoints as outputs shaped by system amplification and context, and we apply this framing to recurring patterns such as preserved analgesia with capped respiratory depression during co-administration and “inadequate intraoperative, adequate postoperative” performance.

2 A simplified operational framework for interpreting perioperative opioid endpoints

We focus on MOR because the worked examples center on MOR agonists; other receptor systems and non-opioid co-medications are treated here as context that can shift system-side amplification and requirements. In the operational framework, observed effect reflects the interaction of drug-side properties (affinity and intrinsic efficacy, ε), system-side properties (effective receptor pool, Rₜ, and downstream gain, γ), and effect-site concentration (C_e), which is shaped by route and barriers (3).

2.1 Operational efficacy (τ): linking ε, Rₜ, and γ

In the Black–Leff operational model, the efficiency with which receptor activation is expressed as an endpoint is summarized by operational efficacy, τ (2). For exposition, we use the shorthand τ ∝ ε·Rₜ·γ, emphasizing that τ depends on both ligand efficacy and system-side amplification. In a normalized form, the effect iswhere ρ is fractional receptor occupancy. Put simply, ρ answers “how much the receptor is occupied,” whereas τ answers “how strongly that occupancy is converted into an effect” in the system under consideration. Thus, the equation states that the effect is determined not by occupancy alone, but by occupancy filtered through system-side amplification. Here, E_sys denotes the theoretical maximal effect of the biological system for that endpoint in the given preparation, whereas E_max denotes the maximal effect attainable by a particular agonist in that state; thus, at near-saturating occupancy (ρ ≈ 1), E_max/E_sys = τ/(1 + τ). For any fixed occupancy, E/E_sys increases monotonically with τ; therefore, high-τ and low-τ endpoints yield qualitatively different occupancy–effect relationships even when receptor pharmacology is unchanged.

E/Esys=(τ⋅ρ)/(1+τ⋅ρ),

This is useful clinically because “full-like” vs. “partial-like” behavior becomes endpoint-relative. For analgesia, the descending pain modulatory system (DPMS) can be treated as a high-τ configuration in which MOR agonists can approach E_sys when sufficiently engaged, whereas respiratory depression can behave as a low-τ configuration in which E_max remains below E_sys even at high occupancy (3, 4). Accordingly, whether affinity or ε differences matter most depends on where the endpoint sits on its τ-shaped curve and on the prevailing context (2).

2.2 Context-dependent performance: τ and minimum required effect (E*)

Here, “context” refers to the perioperative state (e.g., intraoperative vs. postoperative) that shifts both the apparent τ of analgesic control and the minimum required effect (E*). Intraoperatively, E* is typically high and MOR-mediated inhibitory control can behave as a composite moderate-τ configuration; postoperatively, as nociceptive drive subsides and inhibitory control reasserts, E* tends to fall and apparent τ can increase. Accordingly, whether a given occupancy–effect relationship crosses E* depends on the context, not receptor pharmacology alone (5–7) (Figures 1A,B). For a given analgesic endpoint, we treat E_sys as fixed and represent context effects as shifts in τ and E*, rather than by rescaling E_sys. Mechanistically, strong afferent drive can bias the DPMS toward rostral ventromedial medulla (RVM) ON-cell-linked facilitation and away from OFF-cell-linked inhibition, reducing the apparent τ of MOR-mediated inhibitory control (5, 7).

2.3 Determinants of occupancy: affinity and C_e

Receptor occupancy is determined by affinity and the C_e. Here, C_e denotes the agonist concentration at the biophase driving receptor binding. While τ summarizes drug–system transduction, affinity is independent of τ. Affinity is commonly expressed by the equilibrium dissociation constant for a 1:1 binding scheme, K_D = [A][R]/[AR] = k_off/k_on, where [A] is the free agonist concentration, [R] is the free receptor concentration, and [AR] is the agonist–receptor complex concentration; k_off and k_on are dissociation and association rate constants, respectively (2, 4, 8).

Under equilibrium, fractional occupancy is ρ = [A]/([A] + K_D); identifying [A] with C_e yields ρ = C_e/(C_e + K_D), which is conveniently expressed as a function of the dimensionless ratio C_e/K_D (Figures 2A,B). Put simply, occupancy rises as C_e increases relative to K_D, but the relation is hyperbolic rather than linear: when C_e = K_D, occupancy is 50%, and progressively larger increases in C_e are required to push occupancy closer to 1. This is why many clinically relevant regimens remain sub-saturating even for high-affinity ligands. In competitive co-administration at the same receptor population, steady-state occupancy is governed by relative C_e/K_D across agonists, but the observed effect remains endpoint-dependent through τ (9).

Clinically, because occupancy is hyperbolic in C_e/K_D, many regimens are sub-saturating; assuming ρ ≈ 1 can manufacture “paradoxes.”

2.4 Determinants of C_e: route and barriers

C_e depends on route of administration and barrier physiology, so it can diverge from plasma concentration and vary across anatomical targets. With systemic dosing, central C_e is governed by blood–brain barrier transfer, so MOR effects are expressed predominantly through supraspinal circuits relevant to analgesia and respiratory control (5, 10, 11). In contrast, neuraxial or peripheral delivery can preferentially increase spinal or peripheral C_e (dorsal horn or inflamed tissues) while initially limiting supraspinal C_e at comparable analgesic dosing, despite eventual systemic absorption (12–16).

3 Drug exemplars: morphine, fentanyl, and buprenorphine

To anchor the framework in familiar drugs, we sketch three MOR agonists with contrasting efficacy/kinetic profiles. In perioperative care, MOR-mediated analgesia reflects both supraspinal DPMS engagement and spinal dorsal horn inhibition, with their relative contribution shaped by route- and barrier-dependent C_e.

3.1 Morphine

Morphine is a reference MOR agonist and can behave as functionally full-like in high-τ configurations (3). With moderate lipophilicity, it equilibrates centrally more slowly than phenylpiperidines, yet after neuraxial delivery, it can show prolonged spinal residence consistent with sustained dorsal horn MOR engagement (12, 13, 15).

3.2 Fentanyl

Fentanyl has a higher ε than morphine. In the operational framework, higher ε shifts the occupancy required for a strong effect downward, so fentanyl can express large effects at relatively modest occupancy across a range of τ configurations (3).

3.3 Buprenorphine

Buprenorphine has a low ε: it can appear functionally partial-like in low-τ configurations but closer to full-like in high-τ configurations (1, 3). Its slow dissociation from MOR confers high affinity and long residence time, supporting sustained receptor engagement and prolonged analgesic duration even as concentrations decline (17).

4 A τ-based model for MOR agonist co-administration

When two MOR agonists are co-administered and compete for the same receptor population, the receptor-level consequence is occupancy sharing: each agonist takes a share of the same finite MOR pool at the relevant biophase. Their combined effect can be expressed within the competitive-binding form of the receptor operational model (2, 18). In this representation, endpoint differences arise from τ, so the same receptor-level interaction can present as near-additivity in one endpoint yet functional antagonism in another.

For two agonists A and B acting at the same receptor class within a single effector pathway (competitive binding, no allostery), the combined normalized effect can be expressed as follows:where ρ_A and ρ_B are mutually exclusive fractional receptor occupancies (2). In words, τ_eff represents the total operational drive generated by the two agonists after weighting each by both its occupancy and its ability to convert receptor engagement into signaling. Thus, co-administration does not introduce a new receptor principle; it redistributes signaling across the same finite MOR pool, and the clinical appearance of that redistribution still depends on the endpoint's input–output mapping. Practically, co-administration changes the mixture of τ-weighted occupancies (τ_A·ρ_A vs. τ_B·ρ_B); what becomes visible depends on the endpoint's input–output mapping.

E/Esys=τeff/(1+τeff),

τeff=τA⋅ρA+τB⋅ρB,

In high-τ configurations, the occupancy–effect relationship is strongly saturating; therefore, exchanging one agonist for another at high occupancy produces little change in effect, yielding apparent additivity or neutrality. In low-τ configurations, the relationship is closer to proportional over clinically relevant ranges; substituting a high-ε agonist with a low-ε agonist can reduce the effect, i.e., functional antagonism despite both ligands being MOR agonists. These patterns follow from endpoint-dependent τ rather than receptor-level antagonism (4).

5 Discussion

Sections 5.1 and 5.2 give mechanistic explanations: Section 5.1 covers co-administration (occupancy sharing), and Section 5.2 covers state dependence (context-driven shifts in apparent coupling and requirement). Section 5.3 then translates these into bedside heuristics and worked readings.

5.1 Co-administration: preserved analgesia with capped respiratory depression

5.1.1 Buprenorphine co-administered with high-ε MOR agonists

Human data show an endpoint asymmetry that motivates the operational interpretation: buprenorphine produces a ceiling in respiratory depression without a clear analgesic ceiling across clinically relevant dose ranges (1), whereas fentanyl produces dose-dependent respiratory depression without an obvious ceiling (19).

When the two are combined, multiple studies indicate that buprenorphine attenuates fentanyl-induced respiratory depression in an exposure/occupancy-dependent manner, both in healthy volunteers and in opioid-exposed populations (20). A placebo-controlled crossover trial further supports the same principle: sustained high buprenorphine plasma concentrations reduce the magnitude and frequency of fentanyl-induced respiratory depression (21).

Within the operational framework, this pattern follows from endpoint-dependent τ rather than from the order of administration. When buprenorphine and a high-ε MOR agonist are both present, receptor occupancy is shared between them; what differs is how that shared MOR drive is expressed across endpoints. If respiratory control behaves as a low-τ configuration, additional MOR activation has limited dynamic range because the respiratory endpoint approaches its ceiling early. By contrast, analgesic pathways can behave as a high-τ configuration, where a high-ε agonist can reach near-adequate analgesia at relatively low-to-moderate occupancy. In this setting, shifting some occupancy toward buprenorphine does not necessarily produce a proportional loss of analgesia and may appear clinically neutral—or even additive—while further deepening of respiratory depression is constrained. This provides a mechanism-based rationale for using buprenorphine as a “foundation” opioid while reserving high-ε agonists for titratable perioperative analgesia.

5.1.2 Buprenorphine co-administered with neuraxial morphine

Neuraxial morphine can provide robust postoperative analgesia while carrying a risk of delayed respiratory depression, commonly attributed to time-dependent rostral redistribution and increasing supraspinal engagement (22, 23). In the operational framework, neuraxial delivery can generate very high spinal dorsal horn C_e that supports strong analgesia; however, in some patients, morphine may show time-dependent rostral spread within the cerebrospinal fluid, such that brainstem respiratory-circuit C_e rises late. When this delayed supraspinal C_e becomes sufficiently high, respiratory depression can become clinically consequential despite the respiratory endpoint behaving as a low-τ configuration.

Against this background, concomitant systemic buprenorphine offers a mechanistic reason to expect a degree of protection: its high affinity and low-ε partial agonism can plausibly limit further supraspinal MOR drive as rostral morphine exposure accumulates, thereby tempering the depth of respiratory depression, while leaving analgesia largely intact at clinically adequate dosing. Human evidence that buprenorphine attenuates fentanyl-induced respiratory depression in a concentration/occupancy-dependent manner supports the general plausibility of this “partial-agonist cap” in low-τ respiratory circuits (20, 21).

5.2 Intraoperative–postoperative contrast: τ and E*

The same MOR activation can yield different clinical outcomes across contexts. Intraoperatively, intense and rapidly varying nociceptive input lowers effective coupling in DPMS and raises the E*, so that a given receptor occupancy produces a smaller normalized effect and may fail to cross E*. Postoperatively, as nociceptive drive abates, coupling recovers and E* falls, allowing the same ligand to perform adequately at lower occupancy (2, 18).

5.2.1 A high-demand intraoperative state: reduced apparent τ and a high E*

Pain-circuit work has emphasized that strong bottom-up drive can shift descending modulation toward facilitation (reduced net inhibition), often framed as RVM ON-cell dominance with reduced OFF-cell inhibition (5, 7). Here, we treat this shift operationally as a context-dependent reduction in effective inhibitory coupling, i.e., a lower apparent τ for MOR-mediated analgesic control. Consistent with the idea that perioperative E* varies with stimulus intensity, E* can change even within an anesthetized period; for example, under bispectral index-guided propofol anesthesia, the remifentanil C_e required to blunt responses is higher for tracheal intubation than for skin incision (5.0 vs. 2.1 ng/mL) (24).

By contrast, as surgical stimulation resolves and the perioperative state transitions toward recovery, descending inhibitory coupling can reassert itself, effectively shifting the system back toward a high-τ configuration. In parallel, E* typically falls as the nociceptive drive abates. This intra-to-post transition sets the stage for why the same ligand–occupancy relationship may fail intraoperatively yet appear sufficient postoperatively.

5.2.2 Intraoperative adequacy of buprenorphine: high E* in a moderate-τ configuration

Under intense intraoperative nociception, the analgesic system can be viewed as a composite moderate-τ configuration with a high E. Within the operational model, a low-ε* agonist (e.g., buprenorphine) produces less effect at a given occupancy than a high-ε agonist, so achieving E* may require near-saturating occupancy, which is seldom attainable within routine intraoperative dosing ranges (2, 3). This ε-dependent separation of “how much occupancy is needed to reach E*” is illustrated in Figures 1A,B. Because occupancy follows a hyperbolic relationship, pushing occupancy toward 1 demands disproportionately large increases in C_e, yielding diminishing returns (Figures 2A,B). A practical corollary would be matching agonist profiles to the prevailing τ and E* landscape rather than expecting a low-ε agonist to overcome a moderate-τ, high-E* intraoperative state (2, 3).

Many clinicians treat buprenorphine as a fixed “partial agonist,” but in the operational framework, that label is system-relative. The same low-ε agonist can appear full-like for analgesia in high-τ, low-E* contexts yet remain functionally partial for low-τ endpoints such as respiratory depression. It can still underperform intraoperatively when τ falls and E* rises—an alignment that resolves much of the bedside “paradox.”

5.3 Translating the operational model to bedside opioid reasoning

This section translates the operational framework into a small set of bedside reading prompts and illustrates them with recurring perioperative patterns that are often labeled “paradoxical.” The aim is not to prescribe a protocol, but to show how the same MOR-level interaction can look different once endpoint-specific τ and context-specific E* are made explicit.

5.3.1 Bedside reading prompts (concepts, not equations)

Prompt 1: What endpoint am I judging?

Only then decide whether the effect is adequate, inadequate, excessive, or adequate for one output but not for another.

Prompt 2: What other outputs must be checked separately?

A single measure can support endpoint-specific adequacy, but it cannot certify global opioid “success.” Treat “success” as plural and confirm other clinically relevant outputs separately.

5.3.2 Worked bedside readings of recurring patterns

Pattern A: Buprenorphine “foundation” with intraoperative rescue opioid

Common misread: High-affinity “partial agonist” buprenorphine should block full agonists; rescue fentanyl should fail, or, if it works, respiratory depression should scale proportionally.

Endpoint first: Separate intraoperative antinociception (movement/sympathetic responses) from respiratory depression (ventilation/CO₂ control); proportional tracking is not expected.

Operational reading: Co-administration produces occupancy sharing at MOR, but what becomes visible is endpoint-dependent. A short-acting high-efficacy agonist can add enough incremental MOR drive to push an analgesia-related output above the contemporaneous requirement in the operative context, while a low-τ respiratory output may show limited additional dynamic range as it approaches its effective ceiling. The question is not “blocked or not,” but whether the combined MOR drive clears the analgesic requirement at acceptable respiratory cost.

Bedside focus: Treat rescue dosing as a test of the analgesic endpoint and monitor ventilatory outputs separately; the relevant failure mode is failing to meet the analgesic requirement without undue respiratory burden—not “buprenorphine prevents fentanyl from working.”

Pattern B: “Adequate postoperatively” does not back-validate “adequate intraoperatively” with the same opioid

Common misread: Postoperative comfort is taken as evidence that the MOR drive was already “enough” intraoperatively; intraoperative “stability” is then attributed to adequate antinociception, when it may partly reflect the blunted responsiveness of response-generating systems (e.g., arousal/autonomic output) rather than true suppression of nociceptive processing.

Endpoint first: Intraoperative suppression of responses to intense, rapidly varying noxious input vs. postoperative comfort at rest/milder provocation are different outputs with different requirements, and they should not be treated as a single continuous readout of “opioid success.”

Operational reading: Perioperative context shifts both the requirement and the apparent coupling between the MOR input and the analgesia-relevant output (apparent τ). Intraoperatively, a high/variable afferent drive raises the requirement and can reduce the net inhibitory effectiveness (lower apparent τ), so the same MOR engagement may sit below what is needed even if overt responses are muted. Postoperatively, the requirement falls and inhibitory control can recover, so the same MOR engagement can now be above what is needed without any change in receptor identity.

Bedside focus: Treat stimulus-evoked responses as a “requirement not met in this context,” not global opioid failure; and avoid inferring intraoperative adequacy from postoperative adequacy or from intraoperative “stability” alone—confirm analgesia-relevant outputs explicitly in the operative context.

Pattern C: Neuraxial morphine—strong analgesia with delayed respiratory risk

Common misread: Neuraxial morphine is conceptualized as a primarily “spinal” opioid problem (analgesia) with a separate, generic warning about delayed respiratory depression; thus, clinicians do not treat rising supraspinal effect-site concentration as a design variable that can be modulated by a competing MOR agonist.

Endpoint first: Separate analgesia from respiratory depression, and distinguish spinal vs. supraspinal (brainstem) effect-site concentration as the relevant anatomic “where” of expression.

Operational reading: Neuraxial delivery can raise spinal effect-site concentration early (supporting analgesia) while supraspinal/brainstem effect-site concentration is initially limited. With time, rostral spread and systemic absorption can increase brainstem effect-site concentration. If the respiratory endpoint behaves as a low-τ output, clinically meaningful depression can emerge once brainstem MOR engagement exceeds the respiratory requirement, even if the endpoint is ceiling-limited in principle. Framed this way, delayed respiratory depression is the predictable consequence of time-varying effect-site concentration in a different compartment. Importantly, once late supraspinal effect-site concentration is treated as the variable of concern, occupancy sharing becomes conceptually relevant: a high-affinity, low-efficacy MOR agonist could, in principle, limit incremental supraspinal MOR drive as morphine exposure rises, while leaving spinal analgesia largely supported by persistently high spinal effect-site concentration.

Bedside focus: Think explicitly, “where is the effect-site concentration rising now—spinal, supraspinal, or both?”, and monitor/plan for time-dependent output rebalancing; avoid treating delayed respiratory depression as a separate warning divorced from the same MOR-occupancy logic.

5.3.3 Common interpretive traps

Several misreads become less likely once outputs are separated: (i) assuming “high affinity” implies near-total occupancy at typical dosing, despite the hyperbolic C_e–occupancy relation; (ii) expecting proportional changes across outputs (e.g., “if analgesia is present, ventilation or MAC must change similarly”); and (iii) treating co-administration as inherently antagonistic rather than as occupancy sharing whose clinical appearance depends on endpoint-specific τ and the position of E*.

6 Conclusion

Perioperative opioid practice may benefit from moving beyond empiricism toward mechanism-informed design. Within the receptor operational model, phenomena often labeled paradoxes can be understood as consequences of endpoint- and state-dependent τ and E*. Clinically, regimen design can be framed as matching ε, route, and timing to the prevailing τ and E* landscape, recognizing that high-demand perioperative states may lower τ for analgesia while E* rises. A useful upshot of this interpretation is that established perioperative pain-modulation concepts can be expressed as joint shifts in τ and E*, providing a compact language for bedside reasoning.

Generative AI statement

The author(s) declared that generative AI was used in the creation of this manuscript. The author used a generative AI tool (OpenAI; ChatGPT GPT-5.2 Thinking) to assist in refining English phrasing, checking logical consistency, and supporting literature exploration. All cited sources were verified against the original publications, and all scientific content, interpretations, and conclusions were conceived and confirmed by the author, who takes full responsibility for the work.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Footnotes

Edited by: Rene Buchet, Université Claude Bernard Lyon 1, France

Reviewed by: Robert Ruemmler, University Medical Centre, Johannes Gutenberg University Mainz, Germany